Liu et al. (2020) have provided evidence that Brusatol, functioning as an Nrf2 inhibitor, demonstrated inhibitory effects in human NSCLC by instigating ferroptosis through modulation of the FOCAD-FAK signaling pathway. This evidence concerns the gene FOCAD and non-small cell lung carcinoma.